Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment
Globally, cervical cancer is the fourth leading cancer among women and is dominant in resource-poor settings in its occurrence and mortality. This study focuses on developing liquid immunogenic fiducial eluter (LIFE) Biomaterial with components that include biodegradable polymers, nanoparticles, and...
Gespeichert in:
| Veröffentlicht in: | Cancers 2024-03, Vol.16 (6), p.1212 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | 1212 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Moreau, Michele Keno, Lensa S China, Debarghya Mao, Serena Acter, Shahinur Sy, Gnagna Hooshangnejad, Hamed Chow, Kwok Fan Sajo, Erno Walker, Jacques Oh, Philmo Broyles, Eric Ding, Kai Viswanathan, Akila Ngwa, Wilfred |
| description | Globally, cervical cancer is the fourth leading cancer among women and is dominant in resource-poor settings in its occurrence and mortality. This study focuses on developing liquid immunogenic fiducial eluter (LIFE) Biomaterial with components that include biodegradable polymers, nanoparticles, and an immunoadjuvant. LIFE Biomaterial is designed to provide image guidance during radiotherapy similar to clinically used liquid fiducials while enhancing therapeutic efficacy for advanced cervical cancer. C57BL6 mice were used to grow subcutaneous tumors on bilateral flanks. The tumor on one flank was then treated using LIFE Biomaterial prepared with the immunoadjuvant anti-CD40, with/without radiotherapy at 6 Gy. Computed tomography (CT) and magnetic resonance (MR) imaging visibility were also evaluated in human cadavers. A pharmacodynamics study was also conducted to assess the safety of LIFE Biomaterial in healthy C57BL6 female mice. Results showed that LIFE Biomaterial could provide both CT and MR imaging contrast over time. Inhibition in tumor growth and prolonged significant survival (*
< 0.05) were consistently observed for groups treated with the combination of radiotherapy and LIFE Biomaterial, highlighting the potential for this strategy. Minimal toxicity was observed for healthy mice treated with LIFE Biomaterial with/without anti-CD40 in comparison to non-treated cohorts. The results demonstrate promise for the further development and clinical translation of this approach to enhance the survival and quality of life of patients with advanced cervical cancer. |
| doi_str_mv | 10.3390/cancers16061212 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10969426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A788244891</galeid><sourcerecordid>A788244891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-12c62d044e2f2432b9967b894bd1ad9a9c8e5dc42ec847f506cc197a2bca740f3</originalsourceid><addsrcrecordid>eNptUk1P3DAQtVARIMqZW2Wpl14W_LV2fKroCspKK_UCZ8txxsEoscFOVuq_r7dQCgj74NH4vTczT4PQKSVnnGty7mx0kAuVRFJG2R46YkSxhZRafHoVH6KTUu5JPZxTJdUBOuTNkuulkEfIr-MWyhR6O4XY4-kO8G0BnDy2eBMe59Dh9TjOMfUQg8NXoZtdsAO-HOYJMv4R0mhrsEuFiFeQt8HVePW3NXyTwU4jxOkz2vd2KHDy_B6j26vLm9X1YvPr53p1sVk4Ifi0oMxJ1hEhgHkmOGu1lqpttGg7ajtttWtg2TnBwDVC-SWRzlGtLGudVYJ4foy-P-k-zO0Inaulsx3MQw6jzb9NssG8_YnhzvRpayjR1Somq8K3Z4WcHudqjRlDcTAMNkKai-GECkKE0k2Ffn0HvU9zjnU-w2rjmlfL5X9UbwcwIfpUC7udqLlQTcOEaDStqLMPUPV2MAaXIvhQ828I508El1MpGfzLkJSY3XqYd-tRGV9ee_OC_7cM_A8IZ7Zm</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2996930006</pqid></control><display><type>article</type><title>Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Moreau, Michele ; Keno, Lensa S ; China, Debarghya ; Mao, Serena ; Acter, Shahinur ; Sy, Gnagna ; Hooshangnejad, Hamed ; Chow, Kwok Fan ; Sajo, Erno ; Walker, Jacques ; Oh, Philmo ; Broyles, Eric ; Ding, Kai ; Viswanathan, Akila ; Ngwa, Wilfred</creator><creatorcontrib>Moreau, Michele ; Keno, Lensa S ; China, Debarghya ; Mao, Serena ; Acter, Shahinur ; Sy, Gnagna ; Hooshangnejad, Hamed ; Chow, Kwok Fan ; Sajo, Erno ; Walker, Jacques ; Oh, Philmo ; Broyles, Eric ; Ding, Kai ; Viswanathan, Akila ; Ngwa, Wilfred</creatorcontrib><description>Globally, cervical cancer is the fourth leading cancer among women and is dominant in resource-poor settings in its occurrence and mortality. This study focuses on developing liquid immunogenic fiducial eluter (LIFE) Biomaterial with components that include biodegradable polymers, nanoparticles, and an immunoadjuvant. LIFE Biomaterial is designed to provide image guidance during radiotherapy similar to clinically used liquid fiducials while enhancing therapeutic efficacy for advanced cervical cancer. C57BL6 mice were used to grow subcutaneous tumors on bilateral flanks. The tumor on one flank was then treated using LIFE Biomaterial prepared with the immunoadjuvant anti-CD40, with/without radiotherapy at 6 Gy. Computed tomography (CT) and magnetic resonance (MR) imaging visibility were also evaluated in human cadavers. A pharmacodynamics study was also conducted to assess the safety of LIFE Biomaterial in healthy C57BL6 female mice. Results showed that LIFE Biomaterial could provide both CT and MR imaging contrast over time. Inhibition in tumor growth and prolonged significant survival (*
< 0.05) were consistently observed for groups treated with the combination of radiotherapy and LIFE Biomaterial, highlighting the potential for this strategy. Minimal toxicity was observed for healthy mice treated with LIFE Biomaterial with/without anti-CD40 in comparison to non-treated cohorts. The results demonstrate promise for the further development and clinical translation of this approach to enhance the survival and quality of life of patients with advanced cervical cancer.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16061212</identifier><identifier>PMID: 38539546</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Biological products ; Biomaterials ; Cadavers ; Cancer ; Cancer therapies ; Care and treatment ; CD40 antigen ; Cervical cancer ; Cloning ; Computed tomography ; CT imaging ; Disease control ; Ethylenediaminetetraacetic acid ; FDA approval ; Females ; Health aspects ; Human papillomavirus ; Hydrogels ; Immune response ; Immunization ; Immunogenicity ; Investigations ; Magnetic resonance imaging ; Metastases ; Mice ; Nanoparticles ; Pharmacodynamics ; Quality of life ; Radiation therapy ; Radiotherapy ; Survival ; Survival analysis ; Toxicity ; Tumors ; Women</subject><ispartof>Cancers, 2024-03, Vol.16 (6), p.1212</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c443t-12c62d044e2f2432b9967b894bd1ad9a9c8e5dc42ec847f506cc197a2bca740f3</cites><orcidid>0000-0002-6881-6300 ; 0000-0001-6802-0014 ; 0000-0001-7908-3870 ; 0000-0002-1953-0568 ; 0000-0002-8202-0173 ; 0000-0001-9053-8119 ; 0000-0001-7610-8788</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10969426/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10969426/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38539546$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moreau, Michele</creatorcontrib><creatorcontrib>Keno, Lensa S</creatorcontrib><creatorcontrib>China, Debarghya</creatorcontrib><creatorcontrib>Mao, Serena</creatorcontrib><creatorcontrib>Acter, Shahinur</creatorcontrib><creatorcontrib>Sy, Gnagna</creatorcontrib><creatorcontrib>Hooshangnejad, Hamed</creatorcontrib><creatorcontrib>Chow, Kwok Fan</creatorcontrib><creatorcontrib>Sajo, Erno</creatorcontrib><creatorcontrib>Walker, Jacques</creatorcontrib><creatorcontrib>Oh, Philmo</creatorcontrib><creatorcontrib>Broyles, Eric</creatorcontrib><creatorcontrib>Ding, Kai</creatorcontrib><creatorcontrib>Viswanathan, Akila</creatorcontrib><creatorcontrib>Ngwa, Wilfred</creatorcontrib><title>Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Globally, cervical cancer is the fourth leading cancer among women and is dominant in resource-poor settings in its occurrence and mortality. This study focuses on developing liquid immunogenic fiducial eluter (LIFE) Biomaterial with components that include biodegradable polymers, nanoparticles, and an immunoadjuvant. LIFE Biomaterial is designed to provide image guidance during radiotherapy similar to clinically used liquid fiducials while enhancing therapeutic efficacy for advanced cervical cancer. C57BL6 mice were used to grow subcutaneous tumors on bilateral flanks. The tumor on one flank was then treated using LIFE Biomaterial prepared with the immunoadjuvant anti-CD40, with/without radiotherapy at 6 Gy. Computed tomography (CT) and magnetic resonance (MR) imaging visibility were also evaluated in human cadavers. A pharmacodynamics study was also conducted to assess the safety of LIFE Biomaterial in healthy C57BL6 female mice. Results showed that LIFE Biomaterial could provide both CT and MR imaging contrast over time. Inhibition in tumor growth and prolonged significant survival (*
< 0.05) were consistently observed for groups treated with the combination of radiotherapy and LIFE Biomaterial, highlighting the potential for this strategy. Minimal toxicity was observed for healthy mice treated with LIFE Biomaterial with/without anti-CD40 in comparison to non-treated cohorts. The results demonstrate promise for the further development and clinical translation of this approach to enhance the survival and quality of life of patients with advanced cervical cancer.</description><subject>Biological products</subject><subject>Biomaterials</subject><subject>Cadavers</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>CD40 antigen</subject><subject>Cervical cancer</subject><subject>Cloning</subject><subject>Computed tomography</subject><subject>CT imaging</subject><subject>Disease control</subject><subject>Ethylenediaminetetraacetic acid</subject><subject>FDA approval</subject><subject>Females</subject><subject>Health aspects</subject><subject>Human papillomavirus</subject><subject>Hydrogels</subject><subject>Immune response</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Investigations</subject><subject>Magnetic resonance imaging</subject><subject>Metastases</subject><subject>Mice</subject><subject>Nanoparticles</subject><subject>Pharmacodynamics</subject><subject>Quality of life</subject><subject>Radiation therapy</subject><subject>Radiotherapy</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Toxicity</subject><subject>Tumors</subject><subject>Women</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptUk1P3DAQtVARIMqZW2Wpl14W_LV2fKroCspKK_UCZ8txxsEoscFOVuq_r7dQCgj74NH4vTczT4PQKSVnnGty7mx0kAuVRFJG2R46YkSxhZRafHoVH6KTUu5JPZxTJdUBOuTNkuulkEfIr-MWyhR6O4XY4-kO8G0BnDy2eBMe59Dh9TjOMfUQg8NXoZtdsAO-HOYJMv4R0mhrsEuFiFeQt8HVePW3NXyTwU4jxOkz2vd2KHDy_B6j26vLm9X1YvPr53p1sVk4Ifi0oMxJ1hEhgHkmOGu1lqpttGg7ajtttWtg2TnBwDVC-SWRzlGtLGudVYJ4foy-P-k-zO0Inaulsx3MQw6jzb9NssG8_YnhzvRpayjR1Somq8K3Z4WcHudqjRlDcTAMNkKai-GECkKE0k2Ffn0HvU9zjnU-w2rjmlfL5X9UbwcwIfpUC7udqLlQTcOEaDStqLMPUPV2MAaXIvhQ828I508El1MpGfzLkJSY3XqYd-tRGV9ee_OC_7cM_A8IZ7Zm</recordid><startdate>20240320</startdate><enddate>20240320</enddate><creator>Moreau, Michele</creator><creator>Keno, Lensa S</creator><creator>China, Debarghya</creator><creator>Mao, Serena</creator><creator>Acter, Shahinur</creator><creator>Sy, Gnagna</creator><creator>Hooshangnejad, Hamed</creator><creator>Chow, Kwok Fan</creator><creator>Sajo, Erno</creator><creator>Walker, Jacques</creator><creator>Oh, Philmo</creator><creator>Broyles, Eric</creator><creator>Ding, Kai</creator><creator>Viswanathan, Akila</creator><creator>Ngwa, Wilfred</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6881-6300</orcidid><orcidid>https://orcid.org/0000-0001-6802-0014</orcidid><orcidid>https://orcid.org/0000-0001-7908-3870</orcidid><orcidid>https://orcid.org/0000-0002-1953-0568</orcidid><orcidid>https://orcid.org/0000-0002-8202-0173</orcidid><orcidid>https://orcid.org/0000-0001-9053-8119</orcidid><orcidid>https://orcid.org/0000-0001-7610-8788</orcidid></search><sort><creationdate>20240320</creationdate><title>Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment</title><author>Moreau, Michele ; Keno, Lensa S ; China, Debarghya ; Mao, Serena ; Acter, Shahinur ; Sy, Gnagna ; Hooshangnejad, Hamed ; Chow, Kwok Fan ; Sajo, Erno ; Walker, Jacques ; Oh, Philmo ; Broyles, Eric ; Ding, Kai ; Viswanathan, Akila ; Ngwa, Wilfred</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-12c62d044e2f2432b9967b894bd1ad9a9c8e5dc42ec847f506cc197a2bca740f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biological products</topic><topic>Biomaterials</topic><topic>Cadavers</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>CD40 antigen</topic><topic>Cervical cancer</topic><topic>Cloning</topic><topic>Computed tomography</topic><topic>CT imaging</topic><topic>Disease control</topic><topic>Ethylenediaminetetraacetic acid</topic><topic>FDA approval</topic><topic>Females</topic><topic>Health aspects</topic><topic>Human papillomavirus</topic><topic>Hydrogels</topic><topic>Immune response</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Investigations</topic><topic>Magnetic resonance imaging</topic><topic>Metastases</topic><topic>Mice</topic><topic>Nanoparticles</topic><topic>Pharmacodynamics</topic><topic>Quality of life</topic><topic>Radiation therapy</topic><topic>Radiotherapy</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Toxicity</topic><topic>Tumors</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moreau, Michele</creatorcontrib><creatorcontrib>Keno, Lensa S</creatorcontrib><creatorcontrib>China, Debarghya</creatorcontrib><creatorcontrib>Mao, Serena</creatorcontrib><creatorcontrib>Acter, Shahinur</creatorcontrib><creatorcontrib>Sy, Gnagna</creatorcontrib><creatorcontrib>Hooshangnejad, Hamed</creatorcontrib><creatorcontrib>Chow, Kwok Fan</creatorcontrib><creatorcontrib>Sajo, Erno</creatorcontrib><creatorcontrib>Walker, Jacques</creatorcontrib><creatorcontrib>Oh, Philmo</creatorcontrib><creatorcontrib>Broyles, Eric</creatorcontrib><creatorcontrib>Ding, Kai</creatorcontrib><creatorcontrib>Viswanathan, Akila</creatorcontrib><creatorcontrib>Ngwa, Wilfred</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moreau, Michele</au><au>Keno, Lensa S</au><au>China, Debarghya</au><au>Mao, Serena</au><au>Acter, Shahinur</au><au>Sy, Gnagna</au><au>Hooshangnejad, Hamed</au><au>Chow, Kwok Fan</au><au>Sajo, Erno</au><au>Walker, Jacques</au><au>Oh, Philmo</au><au>Broyles, Eric</au><au>Ding, Kai</au><au>Viswanathan, Akila</au><au>Ngwa, Wilfred</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-03-20</date><risdate>2024</risdate><volume>16</volume><issue>6</issue><spage>1212</spage><pages>1212-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Globally, cervical cancer is the fourth leading cancer among women and is dominant in resource-poor settings in its occurrence and mortality. This study focuses on developing liquid immunogenic fiducial eluter (LIFE) Biomaterial with components that include biodegradable polymers, nanoparticles, and an immunoadjuvant. LIFE Biomaterial is designed to provide image guidance during radiotherapy similar to clinically used liquid fiducials while enhancing therapeutic efficacy for advanced cervical cancer. C57BL6 mice were used to grow subcutaneous tumors on bilateral flanks. The tumor on one flank was then treated using LIFE Biomaterial prepared with the immunoadjuvant anti-CD40, with/without radiotherapy at 6 Gy. Computed tomography (CT) and magnetic resonance (MR) imaging visibility were also evaluated in human cadavers. A pharmacodynamics study was also conducted to assess the safety of LIFE Biomaterial in healthy C57BL6 female mice. Results showed that LIFE Biomaterial could provide both CT and MR imaging contrast over time. Inhibition in tumor growth and prolonged significant survival (*
< 0.05) were consistently observed for groups treated with the combination of radiotherapy and LIFE Biomaterial, highlighting the potential for this strategy. Minimal toxicity was observed for healthy mice treated with LIFE Biomaterial with/without anti-CD40 in comparison to non-treated cohorts. The results demonstrate promise for the further development and clinical translation of this approach to enhance the survival and quality of life of patients with advanced cervical cancer.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38539546</pmid><doi>10.3390/cancers16061212</doi><orcidid>https://orcid.org/0000-0002-6881-6300</orcidid><orcidid>https://orcid.org/0000-0001-6802-0014</orcidid><orcidid>https://orcid.org/0000-0001-7908-3870</orcidid><orcidid>https://orcid.org/0000-0002-1953-0568</orcidid><orcidid>https://orcid.org/0000-0002-8202-0173</orcidid><orcidid>https://orcid.org/0000-0001-9053-8119</orcidid><orcidid>https://orcid.org/0000-0001-7610-8788</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2024-03, Vol.16 (6), p.1212 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10969426 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Biological products Biomaterials Cadavers Cancer Cancer therapies Care and treatment CD40 antigen Cervical cancer Cloning Computed tomography CT imaging Disease control Ethylenediaminetetraacetic acid FDA approval Females Health aspects Human papillomavirus Hydrogels Immune response Immunization Immunogenicity Investigations Magnetic resonance imaging Metastases Mice Nanoparticles Pharmacodynamics Quality of life Radiation therapy Radiotherapy Survival Survival analysis Toxicity Tumors Women |
| title | Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T19%3A21%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigating%20the%20Use%20of%20a%20Liquid%20Immunogenic%20Fiducial%20Eluter%20Biomaterial%20in%20Cervical%20Cancer%20Treatment&rft.jtitle=Cancers&rft.au=Moreau,%20Michele&rft.date=2024-03-20&rft.volume=16&rft.issue=6&rft.spage=1212&rft.pages=1212-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16061212&rft_dat=%3Cgale_pubme%3EA788244891%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2996930006&rft_id=info:pmid/38539546&rft_galeid=A788244891&rfr_iscdi=true |